While the debate over whether it’s better to pay for high-quality or high-growth businesses will never end, the easiest solution is to find stocks offering both.
The following company fits this best-of-both-worlds billing, offering leading pet healthcare diagnostics operations. Delivering annualized revenue and free-cash-flow growth of 10% and 25%, respectively, over the past decade, the company’s razor-and-blade model has turned it into a steady compounder.
With the shares now trading at their most reasonable valuation in almost a decade, here are four reasons why this company is one of the most compelling S&P 500 stocks to buy right now.
This post appeared first on Trades Of The Day.